Some Patients with Antiphospholipid Syndrome Express hitherto Undescribed Antibodies to Cardiolipin-binding Proteins

P. Rampazzo; A. Biasiolo; J. Garin; A. Rosato; C. Betterle; A. Ruffatti; V. Pengo

doi:10.1055/s-0037-1612904

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2001; 85(01): 57-62
DOI: 10.1055/s-0037-1612904

Review Article

Schattauer GmbH

Some Patients with Antiphospholipid Syndrome Express hitherto Undescribed Antibodies to Cardiolipin-binding Proteins

P. Rampazzo

¹Department of Clinical and Experimental Medicine, Thrombosis Center, University of Padova, Italy

,

A. Biasiolo

¹Department of Clinical and Experimental Medicine, Thrombosis Center, University of Padova, Italy

,

J. Garin

¹CEA/Grenoble Laboratoire de Chimie des Proteines, Grenoble Cedex, France

,

A. Rosato

²Dept. of Oncology and Surgical Sciences, University of Padova, Italy

,

C. Betterle

³Dept. of Medical and Surgical Sciences, University of Padova, Italy

,

A. Ruffatti

³Dept. of Medical and Surgical Sciences, University of Padova, Italy

,

V. Pengo

¹Department of Clinical and Experimental Medicine, Thrombosis Center, University of Padova, Italy

› Institutsangaben

Abstract

Summary

Contrary to infective anticardiolipin (aCL) antibodies, autoimmune aCL antibodies react with phospholipids (PL) mainly via binding to the plasma glycoprotein cofactor β₂-Glycoprotein I (β₂GPI). While there is a well-documented link between the risk of thrombosis and the presence of β₂GPI-dependent anticardiolipin antibodies, the pathological impact of other antiphospholipid antibodies is less clear. By means of cardiolipin affinity-chromatography, we isolated and identified 3 CL-binding proteins, complement component C4, complement factor H and a kallikrein-sensitive glycoprotein, and tested for the presence of autoantibodies against these proteins in patients with antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and other autoimmune diseases. High titers of autoantibodies to C4 as compared to age- and sex-matched healthy controls were present in 3 of 26 patients with APS, and weak titers were found in 2 of 26 patients with SLE and in none of 26 patients with other autoimmune diseases. Autoantibodies to complement factor H were found in 4 APS, 3 SLE and none of the other autoimmune patients. Autoantibodies to kallikrein-sensitive glycoprotein were detected in 6 APS patients, 1 SLE patient, and 1 patient with another autoimmune disease. A close relationship between these antibodies was found, suggesting their origin from a common macromolecular complex. However, no relationship with anti-β₂GPI antibodies was found, with the three patients with higher levels of autoantibodies having a low titer of anti-β₂GPI antibodies. In conclusion, some patients with APS harbor circulating antibodies to other CL-binding proteins which might be useful to further characterize these patients.

Keywords

Complement component C4 - complement factor H - plasma kallikrein-sensitive glycoprotein - β₂-glycoprotein I

Volltext

Referenzen

References
1 Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J 1983; 287: 1088-9.
2 Harris EN. Syndrome of the Black swan. Br J Rheumatol 1987; 26: 324-6.
3 Asherson RA. A “primary” antiphospholipid syndrome. J Rheumatol 1988; 15: 1742-4.
4 Peaceman AN, Silver RK, MacGregor SN, Socol ML. Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol 1992; 166: 1780-7.
5 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
6 Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, Van Brieda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
7 Matsuura E, Igarashi Y, Fujimoto M, Ichikava K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-8.
8 Matsuura E, Igarashi Y, Yasuda T, Koike T, Triplett DA. Anticardiolipin antibodies recognize β₂-Glycoprotein-I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62.
9 Roubey RAS, Eisemberg RA, Harper MF, Winfield JB. “Anticardiolipin” autoantibodies recognize β₂-Glycoprotein-I in the absence of phospholipids. J Immunol 1995; 154: 954-60.
10 Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β₂-Glycoprotein-I is bound to a suitable surface. Thromb Haemost 1995; 73: 29-34.
11 Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996; 75: 721-4.
12 Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39: 1444-54.
13 Arvieux J, Pernod G, Regnault V, Darnige L, Garin J. Some anticardiolipin antibodies recognize a combination of phospholipids with thrombin-modified antithrombin, complement C4b-binding protein, and lipopolysaccharide binding protein. Blood 1999; 93: 4248-55.
14 Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-^2-Glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899-906.
15 Balestrieri G, Tincani A, Spatola L, Allegri F, Prati E, Cattaneo R, Valesini G, Del Papa N, Meroni P. Anti-β₂-Glycoprotein-I antibodies: a marker of antiphospholipid syndrome?. Lupus 1995; 4: 122-30.
16 Martinuzzo ME, Forastiero RR, Carreras LO. Anti-β₂-Glycoprotein-I antibodies detection and association with thrombosis. Br J Haematol 1995; 89: 397-402.
17 Roubey RAS, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to β₂-Glycoprotein-I and a conventional cardiolipin immunoassay. Arthritis Rheum 1996; 39: 1606-7.
18 Tan EN. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271.
19 Pengo V, Biasiolo A. Purification of anticardiolipin and lupus anticoagulant activities by using cardiolipin immobilized on agarose beads. Thromb Res 1993; 72: 423-30.
20 Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
21 Werner WE, Grimley C, Yuan PM. Effect of polybrene on the N-terminal sequencing of peptides bound to polyvinylidene difluoride membranes. Anal Biochem 1996; 237: 146-9.
22 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4.
23 Pengo V, Balestrieri G, Tincani A, Spatola L, Biasiolo A, Brocco T. Utilization of dilute Russell’s Viper Venom Time to detect autoantibodies against β₂-Glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids. Thromb Haemost 1997; 77: 123-6.
24 Biasiolo A, Rampazzo P, Brocco T, Barbero F, Rosato A, Pengo V. (Antiβ₂ Glycoprotein I – β₂ Glycoprotein I) immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. Lupus 1999; 8: 121-6.
25 Viard JP, Amoura Z, Bach JF. Association of anti-β₂-glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93: 181-6.
26 McNally T, Mackie IJ, Machin SJ, Isenberg DA. Increased levels of β₂ Glycoprotein I antigen and β₂ Glycoprotein I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. J Rheumatol 1995; 34: 1031-6.
27 Amengual O, Atsumi T, Kamashta MA, Koike T, Hughes GVR. Specificity of ELISA for antibody to β₂ Glycoprotein I in patients with antiphospholipid syndrome. J Rheumatol 1996; 35: 1239-43.
28 Galli M, Finazzi G, Bevers E, Barbui T. Kaolin clotting time and dilute Russell’s Viper Venom Time distinguish between prothrombin-dependent and β₂ Glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86: 617-23.
29 Galli M, Barbui T.. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999; 93: 2149-57.
30 Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipid with prothrombin, protein C or protein S: an explanation for their pathogenetic mechanism?. Blood 1993; 81: 2618-25.
31 von Mühlen CA, Chan EKL, Anglés-Cano E, Mamula MJ, Garcia-De La Torre I, Fritzler MJ. Advances in autoantibodies in SLE. Lupus 1998; 7: 507-14.
32 Morgan BP. Physiology and pathophysiology of complement: progress and trends. Crit Rev Clin Lab Sci 1995; 32: 265-98.
33 Hauptmann G, Goetze J, Uring-Lambert B, Grosshans E. Component deficiencies. II. The fourth component. Prog Allergy 1986; 39: 232-49.
34 Wilson WA, Perez MC, Michalski JP, Armatis PE. Cardiolipin antibodies and null alleles of C4 in black americans with Systemic Lupus Erythematosus. J Rheumatol 1988; 15: 1768-72.
35 Kristensen T, Wetsel RA, Tack BF. Structural analysis of human complement protein H: Homology with C4b binding protein, and the Ba fragment of B. J Immunol 1986; 136: 3407-11.
36 Kertesz Z, Yu B, Steinkasserer A, Haupt H, Benham A, Sim RB. Characterization of binding of human β₂-Glycoprotein I to cardiolipin. Biochem J 1995; 310: 315-21.
37 Arnout J, Wittevrongel C, Vermylen J. Phospholipid-binding proteins and the antiphospholipid syndrome: a role for Complement Factor H?. Lupus 1996; 5: 555.
38 Nishimura H, Kakizaki I, Muta T, Sasaki N, Xiao Pu P, Yamashita T, Nagasawa S. cDNA and deduced amino acid sequence of human PK-120, a plasma kallikrein-sensitive glycoprotein. FEBS Letters 1995; 357: 207-11.
39 Colman RW. Biologic activities of the contact factors in vivo. Thromb Haemost 1999; 82: 1568-77.